• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Akeso (SEHK:9926) Is Up 6.8% After Ivonescimab Tops Key Cancer Rivals In Phase III Trials – And What's Next

    Simply Wall St·09/07/2026 15:17:45
    Listen to the news
    • Akeso’s partner Summit Therapeutics reported that Akeso’s PD-1/VEGF bispecific ivonescimab achieved statistically significant overall survival gains over pembrolizumab and durvalumab in separate Phase III trials for PD-L1 positive non-small cell lung cancer and advanced biliary tract cancer, building on prior progression-free survival wins and recent China approvals.
    • This string of head-to-head successes against current immunotherapy standards of care underscores ivonescimab’s potential to reshape Akeso’s oncology footprint across multiple solid tumors.
    • We’ll now examine how ivonescimab’s head-to-head Phase III survival benefits versus current immunotherapy standards could influence Akeso’s broader investment narrative.

    Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

    Akeso Investment Narrative Recap

    To own Akeso today, you need to believe ivonescimab can anchor a broader, commercially viable oncology portfolio before cash burn and competition bite too hard. The latest Phase III overall survival wins versus pembrolizumab and durvalumab sharpen that story, but the near term still hinges on execution in China and timely global approvals, while ongoing losses and dependence on a few drugs remain the central risk.

    Among recent updates, the half year 2026 results matter most here: revenue rose to CNY 1,805.68 million while net loss narrowed to CNY 424.22 million. That mix of improving top line but persistent red ink frames how investors might interpret ivonescimab’s new data: as a potential commercial and reimbursement accelerant, but one that still has to translate into sustainable profitability.

    Yet behind the clinical momentum, investors should be aware that Akeso’s heavy reliance on ivonescimab and cadonilimab leaves the story vulnerable if...

    Read the full narrative on Akeso (it's free!)

    Akeso's narrative projects CN¥11.8 billion revenue and CN¥3.7 billion earnings by 2029.

    Uncover how Akeso's forecasts yield a HK$158.28 fair value, a 65% upside to its current price.

    Exploring Other Perspectives

    SEHK:9926 1-Year Stock Price Chart
    SEHK:9926 1-Year Stock Price Chart

    Before this news, the most optimistic analysts were already assuming Akeso could lift revenue about 74.4% a year and reach roughly CN¥5.7 billion in earnings by 2029, so if you are weighing those upbeat expectations against the fresh trial wins and the concentration risk around ivonescimab, it is worth asking whether this new data ultimately justifies that much optimism or if the story could evolve quite differently.

    Explore 5 other fair value estimates on Akeso - why the stock might be worth as much as 80% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Akeso research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Akeso research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Akeso's overall financial health at a glance.

    No Opportunity In Akeso?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.